Don’t worry about a hep C pricing war, analysts tell Gilead-watchers

Tracy Staton

No price war on hepatitis C drugs? That would be a disappointment to payers worried the cost of treating millions of patients with super-expensive, yet highly effective drugs. But to investors, that reassurance sounds really good.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS